Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.51 |
| ▸ | TUBB | P07437 | 2/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940544 | 1.00 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL29870752 | 1.00 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL807286 | 0.95 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL20163189 | 0.91 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL29870398 | 0.91 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL30940541 | 0.90 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL29870492 | 0.90 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL20163187 | 0.90 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL30940542 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| SCHEMBL29870450 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19RAF1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408082-A1 | METHODS FOR TREATING CANCERS AND TUMORS | BEYONDSPRING PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| US-20240197723-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | BEYONDSPRING PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | claimed |
| US-12377094-B2 | Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies | BeyondSpring Phamaceuticals, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250073231-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | BEYONDSPRING PHARMACEUTICALS, INC. | 2025-03-06 | — | — | US | disclosed |
| US-20240408082-A1 | METHODS FOR TREATING CANCERS AND TUMORS | BEYONDSPRING PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240197723-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | BEYONDSPRING PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-10434098-B2 | Deuterated dehydrophenylahistin compounds and preparation method thereof and use thereof in preparation of anti-tumor drugs | MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20180140600-A1 | DEUTERATED DEHYDROPHENYLAHISTIN COMPOUNDS AND PREPARATION METHOD THEREOF AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS | SHENZHEN HUAHONG MARINE BIOMEDICINE CO., LTD (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434098-B2 | Deuterated dehydrophenylahistin compounds and preparation method thereof and use thereof in preparation of anti-tumor drugs | DHPS, TUBB1, TUBB | CYP1A2 827/4885CYP2C9 1800/4885CYP2C19 964/4885 |
| US-20240197723-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | CD274, CD47, PDCD1 | CYP1A2 3928/4885CYP2C9 4594/4885CYP2C19 4231/4885 |
| US-20180140600-A1 | DEUTERATED DEHYDROPHENYLAHISTIN COMPOUNDS AND PREPARATION METHOD THEREOF AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS | DHPS, DHODH, DHFR | CYP1A2 916/4885CYP2C9 1969/4885CYP2C19 1122/4885 |
| US-20240408082-A1 | METHODS FOR TREATING CANCERS AND TUMORS | BAX, BCL2, CASP3 | CYP1A2 3345/4885CYP2C9 4782/4885CYP2C19 4300/4885 |
| US-20250073231-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | CD274, CD47, PDCD1 | CYP1A2 3928/4885CYP2C9 4594/4885CYP2C19 4231/4885 |
| US-12377094-B2 | Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies | PDCD1, CD274, PDCD1LG2 | CYP1A2 4413/4885CYP2C9 4465/4885CYP2C19 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.